🇺🇸 FDA

Intelligence Platform

Patents

Browse 454 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8614252

Crystalline solid rasagiline base

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8609856

Crystalline forms of Febuxostat

Teva Pharmaceuticals USA, Inc. · Granted Tue Dec 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8598203

Treatment of Crohn's disease with laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8597666

Compressed solid dosage form manufacturing process well-suited for use with drugs of low a

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8592442

Nilotinib HCl crystalline forms

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8580819

Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carbo

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8580293

Monolithic intravaginal rings comprising progesterone and methods of making and uses there

TEVA WOMEN'S HEALTH, INC. · Granted Tue Nov 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8569379

Use of rasagiline for the treatment of olfactory dysfunction

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8563014

Modafinil oral lyophilizate

Teva Sante · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8545885

Stable laquinimod preparations

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8541373

BChE albumin fusions for the treatment of cocaine abuse

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8536149

TRPM-2 antisense therapy

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Sep 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8501766

Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8487097

Reference standard for characterization of rosuvastatin

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jul 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8470344

Aqueous dispersions and solutions of difficult to dissolve materials and methods of their

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8450299

Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Teva Womans's Health, Inc. · Granted Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8426474

Antimicrobial wash and carrier solutions and uses thereof

Teva Animal Health, Inc. · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8414918

Stable imatinib compositions

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8415314

Methods for treating multiple sclerosis using antisense oligonucleotides

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8414920

Pharmaceutical composition containing irbesartan

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8415481

Crystalline form of febuxostat

Teva Pharmaceuticals USA, Inc. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8415332

Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Teva Womans's Health, Inc. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8410267

Regioselective reduction of fused pyrrolocarbazoles-5,7-diones

Teva Sante · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8410288

Polymorphs of Saxagliptin hydrochloride and processes for preparing them

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted